Related Experiment Video
Updated: Jul 28, 2026
The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
Serum levels of soluble interleukin-2 receptor (sIL-2R) in B-chronic lymphocytic leukemia
E Cacciola1, D Calogero, G Marra
1I Cattedra di Ematologia, Università di Catania.
Insights
Researchers measured soluble interleukin-2 receptor (sIL-2R) in chronic lymphocytic leukemia patients. Elevated sIL-2R levels suggest B leukemic cells may release this receptor, impacting immune regulation and potentially serving as a prognostic marker.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Chronic lymphocytic leukemia (B-CLL) is characterized by abnormal immunoregulation.
- The interleukin-2 receptor (IL-2R) plays a crucial role in immune responses.
Purpose of the Study:
- To investigate the levels of soluble interleukin-2 receptor (sIL-2R) in patients with B-CLL.
- To explore the potential source and implications of elevated sIL-2R in B-CLL.
Main Methods:
- Enzyme-linked immunosorbent assay (ELISA) was used to quantify sIL-2R.
- Peripheral blood samples and B cell supernatants from 20 B-CLL patients were analyzed.
Main Results:
- Elevated sIL-2R levels were detected in all serum samples.
- Increased sIL-2R was also found in a subset of B cell supernatants.
Conclusions:
- B leukemic cells may release sIL-2R, contributing to altered immune regulation in B-CLL.
- sIL-2R warrants further investigation for its role in B-CLL pathogenesis and prognostic value.
Abstract:
By using an enzyme-linked immunosorbent assay, the levels of the soluble form of the interleukin-2 receptor (sIL-2R) were evaluated in the peripheral blood of 20 patients with cell chronic lymphocytic leukemia in different stages of disease and in supernatants obtained from enriched B cell suspensions. In either all serum samples or in one out of three supernatants, elevated levels of sIL-2R were found. This could indicate that the B leukemic cells release sIL-2R which in turn, for its potential capacity of binding circulating IL-2, could contribute to the abnormal immunoregulation which characterizes B-CLL. This finding, which needs further investigation, could have prognostic significance.
